全部分类
  • GDC-0994
    GDC-0994的可视化放大

    GDC-0994

    A selective ERK1/2 inhibitor

    此产品仅用于科学研究,我们不为任何个人用途提供产品和服务

    GDC-0994的二维码
    • 库存: 现货
    可选规格
    • 包装
      价格
      促销价
      数量
    • 2mg
      ¥850.00
      680.00
      - +
    • 5mg
      ¥1262.00
      1010.00
      - +
    • 10mg
      ¥2175.00
      1740.00
      - +
    • 50mg
      ¥6300.00
      5040.00
      - +
    已选 0 0
    金额: ¥0.00
    首页 收藏
    • 货号: ajci8254
    • CAS: 1453848-26-4
    • 别名: Ravoxertinib
    • 分子式: C21H18ClFN6O2
    • 分子量: 440.86
    • 纯度: >98%
    • 溶解度: ≥ 44.1mg/mL in DMSO
    • 储存: Store at -20°C
    • 库存: 现货

    Background

    GDC-0994 is a potent and selective inhibitor of ERK1/2 with IC50 values of 1.1 and 0.3 nM, respectively [1].


    The extracellular-signal-regulated kinases (ERK1 and ERK2) are members of the MAP kinase family and act downstream of the RAS/RAF/MEK/ERK signaling cascade that are commonly activated by upstream oncogenic signaling or oncogenic mutations in BRAF or RAS. ERK1/2 play important roles in proliferation, differentiation and cell cycle progression [1].


    GDC-0994 is an orally available and potent ERK1/2 inhibitor with potential antineoplastic activity. In mice bearing KRAS-mutant and BRAF-mutant human xenograft tumors, GDC-0994 exhibited significant single-agent activity and inhibited phospho-p90RSK [1]. When orally administration, GDC-0994 inhibited both activation of ERK-mediated signal transduction pathways and ERK phosphorylation, which then inhibited ERK-dependent tumor cell survival and proliferation.

    参考文献:
    [1].? Robarge K, Schwarz J, Blake J, et al. Abstract DDT02-03: Discovery of GDC-0994, a potent and selective ERK1/2 inhibitor in early clinical development. AACR Annual Meeting, 2014, San Diego, CA.

    Protocol

    Cell experiment [1]:

    Cell lines

    BRAFV600E cell lines

    Preparation method

    The solubility of this compound in DMSO is >22.1mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

    Applications

    In BRAFV600E cell lines, treatment with GDC-0994 resulted in stronger pathway inhibition and subsequent suppression of cell proliferation when compared to BRAF inhibitors.

    Animal experiment [2]:

    Animal models

    Mice bearing KRAS-mutant and BRAF-mutant human xenograft tumors, HT29 colorectal cancer xenograft model.

    Dosage form

    Oral administration, daily

    Application

    Daily, oral administration of GDC-0994 resulted in significant single-agent activity in KRAS-mutant and BRAF-mutant human xenograft tumors in mice.

    Other notes

    Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

    参考文献:

    [1]. Nambu T, Iwai K, Shibata S, et al. Identification of driver of anti-tumor activity of TAK-931 in human colorectal cancer xenograft model[J]. European Journal of Cancer, 2016, 69: S30.


    [2]. Robarge K, Schwarz J, Blake J, et al. Abstract DDT02-03: Discovery of GDC-0994, a potent and selective ERK1/2 inhibitor in early clinical development. AACR Annual Meeting, 2014, San Diego, CA.

    加载中...

    温馨提示 ×
    商品已成功加入购物车!
    购物车共 0 件商品
    去购物车结算
    回到顶部